We are live on
!
Find out more
VIA
Virtus Investment Advisers Portfolio holdings
AUM
$363M
1-Year Est. Return
34.89%
This Fund
S&P 500
This Quarter
Est. Return
+9.26%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$72M
(-20%)
Cap. Flow
-$84.2M
Cap. Flow
% of AUM
-28.48%
Top 10 Holdings %
Top 10 Hldgs %
6.88%
Holding
509
New
39
Increased
197
Reduced
202
Closed
70
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Constellation Energy
CEG
|
+$1.64M |
| 2 |
Veeva Systems
VEEV
|
+$1.51M |
| 3 |
Cisco
CSCO
|
+$1.5M |
| 4 |
Fox Class A
FOXA
|
+$1.48M |
| 5 |
DoorDash
DASH
|
+$1.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
+$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
+$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
+$19M |
| 4 |
SMC
Summit Midstream
SMC
|
+$3.67M |
| 5 |
State Street SPDR Bloomberg High Yield Bond ETF
JNK
|
+$2.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 33.24% |
| 2 | Healthcare | 17.43% |
| 3 | Technology | 12.41% |
| 4 | Industrials | 9.1% |
| 5 | Consumer Discretionary | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNTA
326
DELISTED
Centessa Pharmaceuticals
CNTA
| $103K | 0.03% |
7,810
-1,923
| -20% | -$24.4K |
|
327
AbCellera Biologics
ABCL
$2.12B
| $102K | 0.03% |
29,852
-25,793
| -46% | -$64.2K |
|
328
Nuvation Bio
NUVB
$2.32B
| $101K | 0.03% |
51,952
-10,469
| -17% | -$21.8K |
|
329
Sana Biotechnology
SANA
$980M
| $101K | 0.03% |
37,021
-43,446
| -54% | -$89.6K |
|
330
MoonLake Immunotherapeutics
MLTX
$1.55B
| $101K | 0.03% |
2,136
-914
| -30% | -$37.2K |
|
|
MBX
331
MBX Biosciences
MBX
$3.27B
| $100K | 0.03% |
8,772
+766
| +10% | +$7.8K |
|
332
Scholar Rock
SRRK
$6.44B
| $100K | 0.03% |
2,822
-1,117
| -28% | -$35.1K |
|
333
Celcuity
CELC
$4.52B
| $100K | 0.03% |
7,487
-5,533
| -42% | -$60.2K |
|
334
EyePoint Inc
EYPT
$1.2B
| $99.9K | 0.03% |
10,613
-10,061
| -49% | -$69.5K |
|
|
AUTL
335
Autolus Therapeutics
AUTL
$562M
| $99.7K | 0.03% |
43,736
-17,291
| -28% | -$28.6K |
|
336
Xeris Biopharma Holdings
XERS
$1.45B
| $99.3K | 0.03% |
21,274
-27,014
| -56% | -$124K |
|
337
Summit Therapeutics
SMMT
$11.1B
| $99.3K | 0.03% |
4,664
-4,528
| -49% | -$103K |
|
338
Oric Pharmaceuticals
ORIC
$1.4B
| $98.7K | 0.03% |
9,724
-9,749
| -50% | -$65.4K |
|
339
Olema Pharmaceuticals
OLMA
$1.05B
| $98.7K | 0.03% |
23,161
-1,266
| -5% | -$5.64K |
|
340
Vera Therapeutics
VERA
$2.36B
| $98.4K | 0.03% |
4,176
+539
| +15% | +$12.1K |
|
|
SLNO
341
DELISTED
Soleno Therapeutics
SLNO
| $98.2K | 0.03% |
1,172
-2,371
| -67% | -$177K |
|
|
SLN
342
Silence Therapeutics
SLN
$564M
| $97.7K | 0.03% |
16,837
-8,035
| -32% | -$34.4K |
|
343
Arcutis Biotherapeutics
ARQT
$3.18B
| $97.6K | 0.03% |
6,965
-6,436
| -48% | -$90.2K |
|
344
Apogee Therapeutics
APGE
$10.2B
| $97.5K | 0.03% |
2,246
-1,455
| -39% | -$55.4K |
|
345
Arcturus Therapeutics
ARCT
$211M
| $96.8K | 0.03% |
7,439
-1,914
| -20% | -$22.6K |
|
346
Pharvaris
PHVS
$2.44B
| $96K | 0.03% |
5,457
-3,179
| -37% | -$51.2K |
|
|
SION
347
Sionna Therapeutics
SION
$2.31B
| $96K | 0.03% |
+5,535
| New | +$72.5K |
|
|
ETNB
348
DELISTED
89bio
ETNB
| $96K | 0.03% |
9,775
-11,137
| -53% | -$92.2K |
|
|
RAPP
349
Rapport Therapeutics
RAPP
$2.18B
| $96K | 0.03% |
8,441
-196
| -2% | -$2.08K |
|
350
Enliven Therapeutics
ELVN
$4.43B
| $95.9K | 0.03% |
4,783
-2,359
| -33% | -$44.7K |
|
Similar funds
RC
MS
WI
HS
SIAG
WTFG
A6
ACM
Virtus Investment Advisers's Q2 2025 Portfolio in Review
As of Q2 2025, Virtus Investment Advisers held 509 positions worth $296M, down 20% from $368M the previous quarter. Its ten largest holdings account for 6.9% of the portfolio.
Virtus Investment Advisers withdrew a net $84.2M in Q2 2025, closing 70 positions and reducing 202 holdings. Its most notable exit was Virtus Newfleet ABS/MBS ETF, an estimated $32.2M position sold in full.
By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 24% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Virtus Investment Advisers opened a new position in Constellation Energy worth $2.01M.
- Virtus Investment Advisers's largest Q2 2025 buy was Constellation Energy: 6,213 shares worth $2.01M.
- Virtus Investment Advisers added most to Amgen in Q2 2025, an estimated $1.45M increase.
- Virtus Investment Advisers's biggest Q2 2025 reduction was EOG Resources, cutting an estimated $1.23M.
- Virtus Investment Advisers fully exited Virtus Newfleet ABS/MBS ETF in Q2 2025, selling an estimated $32.2M.
- Virtus Investment Advisers's ten largest holdings make up 6.9% of its $296M portfolio in Q2 2025.
- Virtus Investment Advisers opened 39 new positions and closed 70 in Q2 2025.
- Virtus Investment Advisers's portfolio value fell 20% quarter-over-quarter to $296M.
Based on Virtus Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.